1 / 6

9-10 May 2006 Melbourne

s tream (3b) Topic: (improving management of high cost drugs) One Strike Only Presenter: Professor Michael Dooley Hospital: Bayside Health. 9-10 May 2006 Melbourne. KEY PROBLEMS. Cost of new drugs increasing dramatically with many >$3,000 per pt per month.

lane-cherry
Télécharger la présentation

9-10 May 2006 Melbourne

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. stream (3b)Topic: (improving management of high cost drugs)One Strike Only Presenter: Professor Michael DooleyHospital: Bayside Health 9-10 May 2006Melbourne

  2. KEY PROBLEMS • Cost of new drugs increasing dramatically with many >$3,000 per pt per month. • Usage governed by formal approval process through a Drug & Therapeutics Advisory Committee (DTC). • However, key problems included increasing expenditure relating to: • Multiple “once off” approvals occurring outside the DTC process • Limited audit and review process once drugs approved and initiated • Audit process retrospective consequently not able to influence current prescribing • Evaluation of costs impacts of new drugs unsophisticated

  3. INNOVATIONS IMPLEMENTED • “One strike only” process for new high cost drugs that does not enable multiple “once off approvals”. • DTC approvals constrained in duration & patient numbers that also incorporates formalised review of actual clinical outcomes • DTC approval process that includes formal approval by Finance Committee for those >$50,000 p.a • Prospective “live” database review of all high cost drugs approved • Initiation of costing studies for high costs drugs

  4. RESULTS • Substantial reduction in expenditure on “once off ” drug approvals (approx 50% ) • High cost drugs now approved by DTC require clinician presentation of actual clinical outcomes at six month point for further approval • Formal clinical costing studies of new high cost drugs underway One example of improved prescribing: liposomal amphoterin usage

  5. HOW WE DID IT • Timeframe: 3months from review of existing process to full implementation of new systems • Resources Used: DTC, senior medical & pharmacy management, clinical pharmacists, Drug Information service for independent literature review • Key Success Factors: Change in senior executive management, “fresh eyes”, clinical pharmacists “gate-keeping” prescribing with senior management support

  6. LESSONS LEARNT • Instigate a “one strike” high cost drug policy • Engage senior executive support and ownership • Utilise Drug Information Service for independent review of submissions • Approve new drugs for a limited timeframe and make clinicians present actual outcome data for ongoing access for more patients • Understand and analysis drug costs and potential off-sets/revenue • Engage pharmaceutical industry to support costing studies

More Related